Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Year: 2015
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Tongji University, Shanghai Pulmonary Hospital, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Jiangsu Cancer Hospital, Academy of Military Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Capital Medical University, Beijing Chest Hospital, Peking University Cancer Hospital, Shanghai Jiao Tong University, Shanghai Chest Hospital, Peking Union Medical College Hospital, Sun Yat-sen University Cancer Center, Central South University, Second Xiangya Hospital of Central South University, Xiangya Hospital Central South University, Hunan Cancer Hospital, Cancer Hospital of Shantou University Medical College, Renji Hospital, Soochow University, First Affiliated Hospital of Soochow University, Suzhou University, Xuan Wu Hospital of the Capital Medical University, Zhejiang Cancer Hospital, Second Military Medical University, Shanghai Changzheng Hospital, Nanfang Hospital, Southern Medical University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Award: G8867901477
OpenAlex ID: W2210071992